Intellia Therapeutics’ one-time CRISPR gene editing treatment lonvo-z reduced hereditary angioedema attack rates by 87% in a Phase 3 trial, with more than 60% of patients becoming completely attack-free.

The results, reported by STAT News, arrive at a moment when gene-based and gene editing therapies are undergoing renewed clinical scrutiny. Lonvo-z targets hereditary angioedema (HAE), a rare genetic disorder characterized by episodic, potentially life-threatening swelling of the subcutaneous and submucosal tissues. Attacks can involve the larynx, bowel, or extremities, and carry a mortality risk when airway involvement is present. The American College of Allergy, Asthma, and Immunology estimates that HAE affects approximately one in 50,000 individuals.

The Phase 3 trial enrolled patients with confirmed HAE and documented attack histories. Primary endpoint data showed an 87% reduction in attack rate in the lonvo-z arm. Attack-free status was achieved in over 60% of participants. No serious safety signals were reported during the trial period, a finding that distinguishes this program from several prior gene therapy efforts in rare diseases where hepatotoxicity and immune-mediated adverse events have complicated development.

That safety distinction matters enormously right now.

Astellas Pharma is simultaneously reentering the clinical space with a next-generation gene therapy for X-linked myotubular myopathy (XLMTM), a severe congenital muscle disease caused by mutations in the MTM1 gene. Astellas’ predecessor program, AT132, was previously halted following the deaths of multiple pediatric patients enrolled in the ASPIRO trial. Those deaths, attributed to serious liver-related adverse events including hepatic toxicity, prompted a full clinical hold and cast a long shadow over the XLMTM gene therapy field.

Astellas didn’t walk away. The company’s decision to reenter the clinic with a redesigned construct signals both the severity of the unmet need in XLMTM and the organization’s belief that the prior safety failures were attributable to addressable vector or dosing factors rather than to the therapeutic target itself. XLMTM carries a median survival of fewer than two years without ventilatory support, and there are currently no approved disease-modifying treatments. For families managing the disease, any credible next-generation attempt commands attention.

The parallel between these two programs, one a CRISPR editing therapy for HAE, the other a reinvigorated adeno-associated virus (AAV) gene therapy after fatal setbacks, captures the present tension in the broader gene therapy field. Durable, single-administration treatments have long been the clinical aspiration. The execution has proven far more difficult.

Hereditary angioedema has become something of a proving ground. Current standard-of-care options include subcutaneous C1-inhibitor replacement, lanadelumab (Takhzyro), and the oral plasma kallikrein inhibitor berotralstat (Orladeyo). Prophylactic regimens reduce attack burden but don’t eliminate it for most patients. Lonvo-z, by contrast, aims to address the upstream genetic defect through CRISPR-based editing, theoretically producing durable or permanent effect from a single infusion.

An 87% reduction in attack rate is substantial by any standard in HAE trials.

The absence of serious safety signals deserves particular scrutiny, not because it should be doubted, but because the gene editing field has learned repeatedly that early safety profiles don’t always survive longer follow-up or broader patient exposure. The FDA’s gene therapy guidance framework emphasizes long-term follow-up as a regulatory expectation for all durable genomic interventions, and Intellia will be expected to provide that data in a formal biologics license application (BLA) submission.

Lonvo-z’s mechanism involves CRISPR-Cas9 editing delivered systemically to reduce plasma levels of the proteins that drive bradykinin-mediated angioedema attacks. The therapy’s Phase 3 results, if they hold through regulatory review, would position lonvo-z as a materially different option than anything currently on the HAE formulary. Whether payers will accommodate the pricing that typically accompanies single-administration gene therapies is a separate, unresolved question.

On the oncology side, Eli Lilly said it’s buying Ajax Therapeutics, a privately held blood cancer drug developer, for as much as $2.3 billion. Ajax’s lead asset is a next-generation JAK2 inhibitor currently in a Phase 1 study enrolling patients with myelofibrosis. The acquisition adds to Lilly’s hematology portfolio at a moment when the myelofibrosis treatment space is active with second-generation kinase inhibitor programs attempting to address the limitations of first-generation agents such as ruxolitinib (Jakafi) and fedratinib (Inrebic).

Myelofibrosis remains difficult to treat effectively at the disease-modification level. Existing JAK inhibitors reduce spleen volume and symptom burden but don’t consistently produce bone marrow remission or prolong overall survival in a way that satisfies clinicians or patients. A genuinely next-generation JAK2 inhibitor, if the Phase 1 dose-escalation data support it, could represent a meaningful addition. The $2.3 billion price tag reflects the size of that unmet need and competitive pressure in the space.

Ligand Pharmaceuticals separately announced a $739 million acquisition of Xoma, a royalty aggregator. Drug royalty transactions don’t generate the same clinical commentary as trial readouts, but they reflect the structural maturation of biopharma finance. Royalty-based business models have grown considerably as a capital allocation strategy. Ligand’s move adds Xoma’s royalty portfolio to an already royalty-heavy business model.

Compass Therapeutics reported less favorable news. The company said its drug for advanced biliary cancer delayed tumor progression but didn’t prolong overall survival compared to chemotherapy in a clinical trial. Progression-free survival (PFS) gains without an overall survival (OS) benefit are a recognized problem in oncology trial design. The ACC/AHA’s 2023 framework for cardiovascular endpoints doesn’t directly govern oncology trials, but the broader regulatory science conversation around surrogate versus hard endpoints applies. For biliary tract cancers, where OS data are difficult to generate in adequately powered trials, the failure of a PFS signal to translate into OS benefit is a familiar and discouraging pattern.

BridgeBio shares traded higher following weekend reports that Pfizer settled two of three patent cases related to Vyndamax, its treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Settlement terms weren’t disclosed. Any outcome that extends patent protection for Vyndamax carries secondary implications for BridgeBio’s Attruby, which competes in the same ATTR-CM indication. ATTR-CM is a condition that has moved from a frequently missed diagnosis to one of the more actively contested commercial spaces in cardiology, driven partly by improved cardiac imaging and amyloid-specific scintigraphy protocols and partly by the commercial success of tafamidis since its 2019 approval. Attruby, as the newer entrant, depends in part on the competitive landscape that Vyndamax patent settlements help define.

Back to Intellia. The HAE space has watched CRISPR-based programs with considerable interest since the mechanism’s theoretical advantages over RNA interference (RNAi)-based therapies became apparent in preclinical models. Alnylam’s givosiran and donidalorsen have demonstrated that RNA-targeting approaches can materially reduce HAE attack rates. Lonvo-z’s Phase 3 result, if confirmed in the BLA package, would make a case that editing rather than silencing offers something genuinely different: potentially a one-time correction rather than a treatment that must sustain its effect through ongoing molecular activity.

“We’re very encouraged by the data,” a company representative told STAT News, characterizing the 87% attack rate reduction as evidence of functional disease control.

Functional cure language, when it appears in rare disease communications, carries regulatory weight and commercial consequence. The FDA’s Rare Disease Innovation Hub has signaled an interest in endpoints that reflect patient-meaningful outcomes rather than purely biomarker-based surrogates, and attack-free status in HAE is a patient-meaningful endpoint by any reasonable standard.

The Astellas XLMTM re-entry, the Intellia Phase 3 HAE data, and the Lilly-Ajax acquisition collectively characterize a field that hasn’t been deterred by prior failures so much as recalibrated by them. XLMTM, in particular, is a case where the scientific rationale for gene therapy remains sound even after deaths in a prior trial compelled a full clinical hold. The question Astellas must answer in its next-generation study is whether the redesigned construct produces the neuromuscular benefit seen in some ASPIRO responders while eliminating the hepatic toxicity that proved fatal in others. If that answer is yes, a disease with no approved treatments and a median survival of under two years could, for the first time, have a credible therapeutic option moving through regulatory review.

The field will watch both programs closely through the remainder of 2026.